No Data
No Data
Imagion Biosystems Announces Hybrid General Meeting
Imagion Biosystems Limited invites shareholders to its upcoming General Meeting, to be held both in-person and virtually on August 22, 2024.
Imagion Biosystems Ltd: 2023 Annual Report to shareholders
Imagion Biosystems CEO Resigns
Imagion Biosystems (ASX:IBX) said Isaac Bright resigned as chief executive, effective Monday, to pursue other opportunities. Chair Bob Proulx will resume operating responsibilities as interim executiv
Imagion Biosystems Validates Safety, Feasibility of Breast Cancer Imaging Agent in Phase One Trial; Shares Rise 7%
Imagion Biosystems (ASX:IBX) validated the safety and clinical feasibility of the MagSense HER2 imaging agent following results from a phase one clinical trial. The study met its safety and tolerabili
Argenica Therapeutics Appoints Nonexecutive Chair
Argenica Therapeutics (ASX:AGN) appointed Dianne Angus as nonexecutive chair, effective Dec. 1, succeeding Geoff Pocock. Angus serves as director of Neuren Pharmaceuticals (ASX:NEU), Cyclopharm (ASX:C
Imagion Biosystems Completes Phase 1 Imaging Agent Study
Imagion Biosystems (ASX:IBX) completed its imaging agent phase 1 study for MagSense to help detect human epidermal growth factor receptor 2-positive tumors, according to a Wednesday filing. The trial
No Data